Why Is REPLIMUNE GROUP INC (REPL) Stock Moving Today?

REPLIMUNE GROUP INC stock fell 8.37% to $13.24 in morning trading on September 10, 2026, as multiple law firms announced new class action lawsuits against the company. The lawsuits allege that the company failed to disclose critical issues with its RP1 trial designs, potentially misleading investors. The recent insider selling and ongoing legal challenges appear to have heightened investor concerns.

What Happened

The stock’s sharp decline came as four separate news alerts highlighted the initiation of securities class action lawsuits against Replimune Group. The law firms involved include Bronstein, Gewirtz & Grossman LLC and The Law Offices of Frank R. Cruz. These suits allege that the company did not adequately disclose information about its clinical trial designs, which may have led to investor harm. The filings were announced within a 36-hour window and appear to have triggered immediate selling pressure. Additionally, recent insider transactions show several executives, including the CFO and Chief Medical Officer, sold shares in August.

What The Data Shows

Over the past eight trading sessions, the stock has declined 12.8% from $15.29 to $13.33. The company has a market capitalization of $1.4 billion and has not turned a profit in the trailing twelve months, with an EPS of -3.15. The stock is currently trading within its 52-week range of $1.50 to $16.33 and hit 40 fresh 52-week lows on September 10. Over the past 90 days, insiders have sold five times totaling $1.0 million, with no insider purchases recorded. The stock has a beta of 0.94, slightly less volatile than the market.

What To Watch

Investors should monitor the breadth of legal coverage and any developments regarding the lawsuits. The company has also recently filed a shelf prospectus for an offering, though the size has not been disclosed.